Thread by @NIH

News: Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released dlvr.it/Rrblfv

Data from the Phase 3 #ClinicalTrial for @JanssenGlobal’s single dose #COVID19 vaccine shows it's 85% effective in preventing severe disease & completely protects against hospitalization & death, including from variant strains in the U.S., Latin America, & South Africa. (1/4)

Overall results showed the vaccine is 72% effective in the U.S. at preventing moderate (generally symptomatic #COVID19 that could include symptoms ranging from cough, sore throat and fever to pneumonia, difficulty breathing, & deep vein thrombosis) & severe illness. (2/4)

Results also indicate overall efficacy of 66% across all regions and including highly infectious variants in the U.S., Latin America & South Africa. The vaccine was partially funded by #NIH @NIAIDNews, @HHSGov & @BARDA via the Federal COVID-19 response. (3/4)

Thank you to all the volunteers in the #COVID19 trials and the teams at the clinical research sites for their contributions to the scientific process during the pandemic. We must continue clinical trial enrollment to aid in the vaccine development process. (4/4)